In the course of our screening program for a new topoisomerase inhibitor from culture broths, strain BA10988was found to produce an active component, designated BE-10988. This compoundwas considered to be a new one, based on its physico-chemical properties. This paper describes the taxonomy of the producing strain and the fermentation, isolation and physico-chemical and biological properties of BE-10988. The structure of BE-10988 is shown in Fig. 1 . The structure elucidation studies by spectral analyses, chemical derivation and total svnthesis will be reported separately.
Taxonomyof the Producing Organism
Strain BA10988was isolated from a soil sample collected in Takatsuki, Osaka Prefecture, Japan. Characterization of the strain followed the method adopted by the International Streptomyces Project (ISP)1*, and several other tests were also used. Microscopic studies showed that long, straight in Table 1 . Aerial mass color of the colony was grayish white to yellowish gray. Reverse-side growth was olive to yellowish green. Melanoid and other soluble pigments were not produced. The physiological properties and utilization of carbon sources of strain BA10988 are shown in Tables 2 and 3 . The hydrolyzed cell wall of the strain contained l,ldiaminopimelic acid and glycine. Accordingly, the cell wall of the strain was classified as type I. Based on the taxonomic properties described above, strain BA10988is considered to belong to the genus Streptomyces. Amongthe known Streptomyces species, S. fimicarius and S. xanthocidicus are recognized to be similar to strain BA10988. The results of direct comparison of strain BA10988and these two species are summarized in Table 3 . Strain BA10988 is related to S. fimicarius and S. xanthocidicus in microbiological properties, but it differs considerably from these two type strains in the utilization of carbon sources. The strain, Streptomyces sp. BA10988, has been deposited in the Fermentation Research Institute, Agency of Industrial Topoisomerase Assay The assay procedure (K/SDS assay) used for screening and detection of active fractions was based essentialy on the method of Trask et al.2) and modified as reported previously3). Briefly, P388 cells were prelabeled with [3H]thyrmdine. After the incubation with samples P388 cells were lysed in SDSsolution and the DNAwas sheared by pipetting. Protein-linked DNAwas co-precipitated with K/SDS and the radioactivity in the precipitates which represents the relative amountof DNA-topoisomerasecomplex was counted.
Fermentati on
Spores of strain BA10988 were inoculated into several 500-ml Erlenmeyer flasks each containing 100ml of a medium composed of glucose 0.1%, dextrin 2.0%, corn gluten meal 1.0%, fish meal 0.5%, yeast extract 0.1%, NaCl 0.1%, MgSO4-7H2O 0.05%, CaCl2-2H2O 0.05%, FeSO4-7H2O 0.0002%, CuCl2-2H2O 0.0004%, MnCl2-4H2O 0.0004%, CoCl2-6H2O 0.0004%, ZnSO4-7H2O 0.00008%, Na2B4O7 à" 10H2O 0.00008%, (NH4)6Mo7O24 à" 4H2O 0.00024% and 3-(7V-morpholino)propanesulfonic acid 0.5% and cultured at 28°C for 3 days on a rotary shaker. Twomlof the seed culture were inoculated into each of one hundred of 500-ml Erlenmeyer flasks containing 100ml of the above medium and cultured at 28°C for 5 days on a rotary shaker.
Isolation
The cultured whole broth (ca. 10 liters) was extracted with 10 liters (5 liters x 2) of EtOAc, the EtOAc layer was concentrated in vacuo and 13.7g of oily crude material was obtained. This crude material was subjected to silica gel chromatography (3x30cm) and the column was developed by a solvent (CHC13 -EtOAc from 1 : 1 to 1 : 3) stepwise, and active material-containing fractions were obtained. From the active fractions, 374mgof crude material was obtained by evaporation in vacuo. This crude material was dissolved in 200ml of A^,A^-dimethylformamide-MeOH (1 : 1) and subjected to HPLC (Develosil ODS-10/20, 5 x 50cm, eluting solvent: 24% CH3CN, flow rate: 100ml/minute). The BE-10988-containing fraction (ca. 2.2 liters) obtained by HPLC was kept at 0°C for 3 days and the resulting dark-red crystalline precipitates of BE-10988 were collected (45 mg). Biological Properties BE-10988 produced DNA-topoisomerase complex in L1210 cells in a dose dependent manner to the extent of 3^g/ml. This effect was about three times stronger than that of VP-16, a nonintercalative topoisomerase-II inhibitor. At concentrations over 3 /xg/ml the complex formation was gradually reduced, as in the case ofintercalative topoisomerase-II inhibitors such as doxorubicin, ellipticine and mitoxantrone.
Physico-chemical Properties
The growth inhibitory activity of BE-10988 against P388 mouse tumor cells was evaluated. Doxorubicin-resistant P388 cells (P388/ADR), vincristine-resistant cells (P388/VCR) and their parental cells (P388/S)4) were suspended in RPMI medium containing 10% FBS at a density of 2.5 x 104 cells/ml. BE-10988 was dissolved in dimethyl sulfoxide and 2 jA of serially diluted solution was incubated with 200 fi\ of cell suspension under 5% CO2at 37°C for 72 hours. The number of cells was counted by a Coulter Counter and the IC50 value (concentration required for 50% inhibition of cell growth) was calculated. BE-10988 markedly inhibited the growth of not only P388*/S cells but also P388/VCR and P388/ADR cells. The IC50 values were 0.5, 0.4 and 2.0/iM for P388/S, P388/VCR and P388/ADR cells, respectively.
Discussion
Anantitumor substance having a newstructure is always desired as a newlead for chemotherapeutic agents. It is known that the topoisomerases are the target enzymes of antitumor drugs, since DNA topoisomerases-I and -II are critical nuclear enzymes which regulate the three dimensional structure of DNA.Several cytotoxic agents such as amsacrine, doxorubicin and epipodophyllotoxins induce topoisomerase-II mediated cleavage of DNAin vitro5~12). Camptothecin, a potent cytotoxic plant alkaloid induces topoisomerase-I mediated single strand cleavage of DNAin vitro13'14). These clinically useful drugs appear to stabilize topoisomerase-DNA covalent complexes, which can be trapped as cleavable complexes upon denaturation. Thus we screened for inhibitors of topoisomerase by using the K/SDS assay and succeeded in finding a new compound, BE-10988. BE-10988 inhibited the relaxation of pBR322 plasmid DNAby topoisomerase-II, as will be reported elsewhere. It should be pointed out that this topoisomerase inhibitor inhibits the growth of vincristine-resistant doxorubicin-resistant P388 cell lines that are known to contain and express an amplified gene, mdrl, which is transcribed into a 4.5-kilobase mRNA and translated into a 1 70-kilodaltone membrane glycoprotein that participates in increased drug efflux1 5). Thus, we hope that BE-10988 might be a new lead for antitumor agents. Further biochemical and biological studies are in progress.
